Byetta surging not just for diabetes

The successful new diabetes prescription drug Byetta (exenatide) has been present on the American market for just over nine months, but already it is attracting a large and growing following. This is not just because of its role in the treatment of diabetes, but also because it is an effective way to lose weight.
Byetta is supposed to mimic the effects of naturally occurring hormones within the intestines, and was approved by the FDA (Food and Drug Administration) in order to help adults with type 2 diabetes control blood sugar levels. Rumours are circulating that one side-effect of the drug is the ability for users to shed significant amounts of fat.
Clinical trials conducted in order to get the drug approved by the FDA gave substance to the storied by reporting that Byetta trial participants also lost weight during the course of the trial.
Byetta, although it has not been actively marketed to consumers as of yet, is being marketed to the healthcare industry by Amylin Pharmaceuticals and Eli Lilly. They actively state that Byetta is a diabetes-only drug, and should under no circumstances be used by non-diabetics as a diet drug. No Byetta trials for non-diabetic patients have been conducted or are planned. Byetta is only available by injection.